The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan. Objective: To ...

Please provide your email address to receive an email when new articles are posted on . Adherence to sacubitril/valsartan was relatively good, at about 86% of prescribed patients with HF, but ...

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries. Results from 2 investigations highlight the mixed ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — In a real-world population of patients hospitalized for HF with reduced ejection fraction, ...

Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril–valsartan therapy is safe and effective among ...

Prague, Czechia – 21 May 2023: Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilisation for worsening heart failure in patients with ...

In patients with symptomatic heart failure, sacubitril–valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an ...

PHILADELPHIA — Even the sickest of patients with acute heart failure (HF) can be safely started on sacubitril/valsartan (Entresto, Novartis) in the intensive-care unit (ICU) as part of their careful ...

Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to ...